Floatz logo

Tislelizumab

Hepatic Metastasis of Pancreatic Cancer

Ruijin Hospitalmonoclonal_antibodyPhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hepatic Metastasis of Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Tegodor
Ruijin Hospital
Phase 2B

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →